Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Neurochemistry

• Publication date

  2003-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1471-4159.2003.t01-1-01868.xPMID 12807446
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease

  2002cited by this paper
• Interaction of Huntington Disease Protein with Transcriptional Activator Sp1

  2002cited by this paper
• Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease

  2002cited by this paper
• Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease

  2002cited by this paper
• Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines

  2002cited by this paper
• Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.

  2002cited by this paper
• Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin.

  2002cited by this paper
• Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease

  2001cited by this paper
• Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity

  2001cited by this paper
• Early and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain

  2001cited by this paper
• Exploitation of the HIV‐1 coat glycoprotein, gp120, in neurodegenerative studies in vivo

  2001cited by this paper
• Increased oxidative damage to DNA in ALS patients.

  2000influential reference
• Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.

  2000cited by this paper
• Transcriptional dysregulation in Huntington's disease.

  2000cited by this paper
• The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

  2000cited by this paper
• Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse

  2000cited by this paper
• Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

  2000influential reference
• Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease.

  2000cited by this paper
• Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

  2000cited by this paper
• Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

  1999cited by this paper
• Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease.

  1999cited by this paper
• Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

  1996cited by this paper
• Aging, energy, and oxidative stress in neurodegenerative diseases

  1995cited by this paper
• Ubiquinone Protects Cultured Neurons against Spontaneous and Excitotoxin-Induced Degeneration

  1992cited by this paper
• THE SUBMERGENCE OF WESTERN EUROPE PRIOR TO THE NEOLITHIC PERIOD.

  1895cited by this paper

• Synthetic and semi-synthetic antioxidants in medicine and food industry: a review

  2025cites this paper
• Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov

  2024cites this paper
• Cell Rearrangement and Oxidant/Antioxidant Imbalance in Huntington’s Disease

  2023cites this paper
• From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research

  2023cites this paper
• Neurodegenerative disease: New hopes and perspectives.

  2023cites this paper
• Recent developments in the management of Huntington's disease.

  2022cites this paper
• Therapeutic Advances for Huntington’s Disease

  2020cites this paper
• Twist1 Plays an Anti-apoptotic Role in Mutant Huntingtin Expression Striatal Progenitor Cells

  2019cites this paper
• Therapeutics Advancement for Huntington Disease

  2019cites this paper
• Deuterium‐reinforced linoleic acid lowers lipid peroxidation and mitigates cognitive impairment in the Q140 knock in mouse model of Huntington's disease

  2018cites this paper
• Huntington's disease: Current and future therapeutic prospects

  2018cites this paper
• New directions in therapeutics for Huntington disease.

  2018cites this paper
• 7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington’s disease mouse model through specific activation of the PLC&ggr;1 pathway

  2017cites this paper
• Investigational agents for the management of Huntington’s disease

  2017cites this paper
• Altered Aconitase 2 Activity in Huntington’s Disease Peripheral Blood Cells and Mouse Model Striatum

  2017cites this paper
• Effects of Anthocyanins on CAG Repeat Instability and Behaviour in Huntington’s Disease R6/1 Mice

  2016cites this paper
• Time-Course Analysis of Protein and Lipid Oxidation in the Brains of Yac128 Huntington's Disease Transgenic Mice

  2016cites this paper
• Novel targets for Huntington’s disease: future prospects

  2016cites this paper
• Pridopidine for the treatment of Huntington’s disease

  2016cites this paper
• The role of axonal transport and mitochondrial dysfunction in neurodegeneration-focusing on Huntington's disease

  2015cites this paper
• The discovery and development of new potential antioxidant agents for the treatment of neurodegenerative diseases

  2014cites this paper
• AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.

  2014cites this paper
• Antioxidative defense mechanisms controlled by Nrf2: state-of-the-art and clinical perspectives in neurodegenerative diseases

  2014cites this paper
• The role of oxidative stress in Huntington's disease: are antioxidants good therapeutic candidates?

  2014cites this paper
• Do glial cells play an anti-oxidative role in Huntington's disease?

  2014cites this paper
• Mouse Models of Polyglutamine Diseases in Therapeutic Approaches: Review and Data Table. Part II

  2012cites this paper
• Consequences of Mitochondrial Dysfunction in Huntington's Disease and Protection via Phosphorylation Pathways

  2012cites this paper
• Antioxidants in Huntington's disease.

  2012cites this paper
• Energy Metabolism in Huntington’s Disease

  2012cites this paper
• Energy deficit in Huntington disease: why it matters.

  2011cites this paper
• Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease.

  2011cites this paper
• BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.

  2011cites this paper
• Experimental models of HD and reflection on therapeutic strategies.

  2011cites this paper
• HUNTINGTON DISEASE: CURRENT ADVANCES IN PATHOGENESIS AND RECENT THERAPEUTIC STRATEGIES

  2011cites this paper
• Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.

  2010cites this paper
• Mitochondria in Huntington's disease.

  2010cites this paper
• The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.

  2009cites this paper
• Emerging drug therapies in Huntington's disease

  2009cites this paper
• Murine models of Huntington disease

  2009cites this paper
• Antioxidants cannot suppress the lethal phenotype of a Drosophila melanogaster model of Huntington's disease.

  2008cites this paper
• Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease?

  2008cites this paper
• Animal welfare and the refinement of neuroscience research methods – a case study of Huntington's disease models

  2008cites this paper
• New Targets for Therapy in Polyglutamine (polyQ) Expansion Diseases

  2008cites this paper
• CHAPTER 6 – Huntington Disease

  2008cites this paper
• Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

  2008cites this paper
• Evidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants

  2008cites this paper
• Pharmacological properties of BN82451: a novel multitargeting neuroprotective agent.

  2007cites this paper
• ETUDE DE L'AMPLIFICATION DE LA NEURODEGENERESCENCE EXCITOTOXIQUE PAR UNE DYSFONCTION MITOCHONDRIALE : IMPLICATIONS POUR LA MALADIE DE HUNTINGTON

  2006cites this paper
• The identification of chemical compounds that decrease cellular levels of toxic Huntington's disease protein through a novel cell-based assay

  2006cites this paper
• Chapter 14 - Molecular Pathogenesis and Therapeutic Targets in Huntington's Disease

  2006cites this paper
• Mouse models of triplet repeat diseases

  2006cites this paper
• Mouse models of triplet repeat diseases.

  2006cites this paper
• Oxidative Damage in Huntington's Disease Pathogenesis

  2006cites this paper
• Huntington’s Disease: Mechanisms Of Pathogenesis And Development Of New Therapies

  2005cites this paper
• Characterization and use of the YAC128 mouse model of HD

  2005cites this paper
• Alternatives to Levodopa in the Initial Treatment of Early Parkinson’s Disease

  2005cites this paper
• A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules

  2005cites this paper
• Novel therapeutic targets for Huntington’s disease

  2005cites this paper
• The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies

  2005cites this paper
• Characterization and treatment of mouse models of Huntington disease

  2005cites this paper
• Thiazole derivatives for treating dyskinesias

  2005cites this paper
• Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.

  2005cites this paper
• Phenolic thiazoles as novel orally-active neuroprotective agents.

  2004cites this paper
• Effects of α-tocopherol on an animal model of tauopathies

  2004cites this paper
• Translating therapies for Huntington’s disease from genetic animal models to clinical trials

  2004cites this paper
• Experimental therapeutics in transgenic mouse models of Huntington's disease

  2004cites this paper
• Huntington's disease: which drugs might help patients?

  2004cites this paper
• Effects of alpha-tocopherol on an animal model of tauopathies.

  2004cites this paper